Ali Tabarroki

Family Medicine | Intensive Care Medicine | Geriatrics

135 Bloomfield Avenue
Bloomfield, NJ 07003

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.

Journal: American journal of hematology

Published: November 10, 2015

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Journal: Leukemia & lymphoma

Published: May 06, 2015

Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Journal: Leukemia & lymphoma

Published: May 01, 2015

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 12, 2015

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia.

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia.

Journal: Leukemia & lymphoma

Published: October 21, 2014

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.

Journal: Journal of hematology & oncology

Published: October 13, 2014

Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.

Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.

Journal: Leukemia & lymphoma

Published: June 24, 2014

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.

Journal: Leukemia & lymphoma

Published: April 29, 2014

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Journal: American journal of hematology

Published: March 20, 2014

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

Journal: Leukemia research

Published: February 07, 2014

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

Journal: Leukemia

Published: January 15, 2014

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Journal: Leukemia

Published: December 12, 2013

Showing 1-12 of 21

Last Updated: 09/26/2026